Emerging immunomodulatory therapies targeting the co-stimulatory pathways for the prevention of transplant rejection

IDrugs

Volumn 6, Issue 10, 2003, Pages 964-969

  Ansari, Mohammed Javeed I ^a   Abdi, Reza ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Anti CD154; CD40; Co stimulation; CTLA4Ig; ICOS; PD 1; Tolerance; Transplantati on

Indexed keywords

2 CYANO 3 HYDROXY N [4 (TRIFLUOROMETHYL)PHENYL] 6 HEPTYNAMIDE; ABI 793; ANTIBODY; B7 ANTIBODY; BELATACEPT; CD134 LIGAND MONOCLONAL ANTIBODY; CD40 LIGAND MONOCLONAL ANTIBODY; CD86 ANTIBODY; CORTICOSTEROID; CYCLOSPORIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FINGOLIMOD; HUMANIZED B7 ANTIBODY; HUMANIZED CD28 ANTIBODY; HUMANIZED CD86 ANTIBODY; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INDUCIBLE COSTIMULATORY ANTIBODY; INDUCIBLE COSTIMULATORY IMMUNOGLOBULIN; INTERLEUKIN 2 RECEPTOR MONOCLONAL ANTIBODY; JAK 3; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY IDEC 131; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; SPHINGOSINE 1 PHOSPHATE; STEROID; TACROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE GRAFT REJECTION; ADD ON THERAPY; ADJUVANT THERAPY; ALLOIMMUNITY; ANTIBODY AFFINITY; BLOOD VESSEL GRAFT; CHRONIC GRAFT REJECTION; CLINICAL TRIAL; DIABETES MELLITUS; DRUG ANTAGONISM; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; ENCEPHALOMYELITIS; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEART GRAFT; HUMAN; IMMUNOMODULATION; IMMUNOSTIMULATION; INHIBITION KINETICS; KIDNEY ALLOGRAFT REJECTION; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MONOTHERAPY; NONHUMAN; POSTOPERATIVE COMPLICATION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SKIN DISEASE; SKIN TRANSPLANTATION; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; THROMBOEMBOLISM; TRANSFUSION; TRANSPLANTATION TOLERANCE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, MONOCLONAL; DRUG DELIVERY SYSTEMS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; SIGNAL TRANSDUCTION;

EID: 0142183197     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D: Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med (2000) 342(9):605-612.
2. Takemoto SK, Terasaki PI, Gjertson DW, Cecka JM: Twelve years' experience with national sharing of HLA-matched cadaveric kidneys for transplantation. N Engl J Med (2000) 343(15):1078-1084.
3. Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, Neylan J, Wilkinson A, Ekberg H, Gaston R, Backman L, Burdick J: Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med (1998) 338(3):161-165.
4. Kahan BD, Rajagopalan PR, Hall M: Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. Transplantation (1999) 67(2):276-284.
5. Gaber AO, First MR, Tesi RJ, Gaston RS, Mendez R, Mulloy LL, Light JA, Gaber LW, Squiers E, Taylor RJ, Neylan JF et al: Results of the double-blind, randomized, multicenter, phase III clinical trial of thymoglobulin versus atgam in the treatment of acute graft rejection episodes after renal transplantation. Transplantation (1998) 66(1):29-37.
6. Krensky AM, Weiss A, Crabtree G, Davis MM, Parham P: T-lymphocyte-antigen interactions in transplant rejection. N Engl J Med (1990) 322(8):510-517.
7. Bluestone JA: New perspectives of CD28-B7-mediated T cell costimulation. Immunity (1995) 2(6):555-559.
8. June CH, Bluestone JA, Nadler LM, Thompson CB: The B7 and CD28 receptor families. Immunol Today (1994) 15(7):321-331.
9. Linsley PS, Ledbetter JA: The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol (1993) 11:191-212.
10. Sayegh MH, Turka LA: The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med (1998) 338(25):1813-1821.
11. Schwartz JC, Zhang X, Nathenson SG, Almo SC: Structural mechanisms of costimulation. Nat Immunol (2002) 3(5):427-434.
12. Suthanthiran M, Strom TB: Renal transplantation. N Engl J Med (1994) 331(6):365-376.
13. Salomon B, Bluestone JA: Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol (2001) 19:225-252.
14. Reiser H, Stadecker MJ: Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. N Engl J Med (1996) 335(18):1369-1377.
15. L restores cell survival, but not proliferation of effector differentiation, in CD28-deficient T lymphocytes. J Exp Med (2000) 191(12):2031-2038.
16. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA: CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med (1991) 174(3):561-569.
17. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson CB, Bluestone JA: CTLA-4 can function as a negative regulator of T cell activation. Immunity (1994) 1(5):405-413.
18. Greenwald RJ, Boussiotis VA, Lorsbach RB, Abbas AK, Sharpe AH: CTLA-4 regulates induction of anergy in vivo. Immunity (2001) 14(2):145-155.
19. Greenwald RJ, Latchman YE, Sharpe AH: Negative co-receptors on lymphocytes. Curr Opin Immunol (2002) 14(3):391-396.
20. Lin H, Bolling SF, Linsley PS, Wei RQ, Gordon D, Thompson CB, Turka LA: Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J Exp Med (1993) 178(5):1801-1806.
21. Sayegh MH, Akalin E, Hancock WW, Russell ME, Carpenter CB, Linsley PS, Turka LA: CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J Exp Med (1995) 181(5):1869-1874.
22. Tran HM, Nickerson PW, Restifo AC, Ivis-Woodward MA, Patel A, Allen RD, Strom TB, O'Connell PJ: Distinct mechanisms for the induction and maintenance of allograft tolerance with CTLA4-Fc treatment. J Immunol (1997) 159(5):2232-2239.
23. Levisetti MG, Padrid PA, Szot GL, Mittal N, Meehan SM, Wardrip CL, Gray GS, Bruce DS, Thistlethwaite JR Jr, Bluestone JA: Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. J Immunol (1997) 159(11):5187-5191.
24. Lenschow DJ, Zeng Y, Hathcock KS, Zuckerman LA, Freeman G, Thistlethwaite JR, Gray GS, Hodes RJ, Bluestone JA: Inhibition of transplant rejection following treatment with anti-B7-2 and anti-B7-1 antibodies. Transplantation (1995) 60(10):1171-1178.
25. Lenschow DJ, Zeng Y, Thistlethwaite JR, Montag A, Brady W, Gibson NG, Linsley PS, Bluestone JA: Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science (1992) 257(5071):789-792.
26. Adams AB, Shirasugi N, Durham MM, Strobert E, Anderson D, Rees P, Cowan S, Xu H, Blinder Y, Cheung M, Hollenbaugh D et al: Calcineurin inhibitor-free CD28 blockade-based protocol protects allogeneic islets in nonhuman primates. Diabetes (2002) 51(2):265-270.
27. Moreland LW, Alten R, Van Den Bosch F, Appelboom T, Leon M, Emery P, Cohen S, Luggen M, Shergy W, Nuamah I, Becker JC: Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum (2002) 46(6):1470-1479.
28. Cabrian KM, Berry KK, Shuford WW, Mittler RS, Rodgers JN, Linsley PS: Suppression of T-cell-dependent immune responses in monkeys by CTLA4Ig. Transplant Proc (1996) 28(6):3261-3262.
29. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH: Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity (1995) 3(5):541-547.
30. Perez VL, Van Parijs L, Biuckians A, Zheng XX, Strom TB, Abbas AK: Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity (1997) 6(4):411-417.
31. Lin H, Rathmell JC, Gray GS, Thompson CB, Leiden JM, Alegre ML: Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA4 can function independently of CD28. J Exp Med (1998) 188(1):199-204.
32. Yu XZ, Martin PJ, Anasetti C: Role of CD28 in acute graft-versus-host disease. Blood (1998) 92(8):2963-2970.
33. Yu XZ, Bidwell SJ, Martin PJ, Anasetti C: CD28-specific antibody prevents graft-versus-host disease in mice. J Immunol (2000) 164(9):4564-4568.
34. Abrams JR, Lebwohl MG, Guzzo CA, Jegasothy BV, Goldfarb MT, Goffe BS, Menter A, Lowe NJ, Krueger G, Brown MJ, Weiner RS et al: CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest (1999) 103(9):1243-1252.
35. Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A, Bluestone JA: B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity (2000) 12(4):431-440.
36. Reul RM, Fang JC, Denton MD, Geehan C, Long C, Mitchell RN, Ganz P, Briscoe DM: CD40 and CD40 ligand (CD154) are coexpressed on microvessels in vivo in human cardiac allograft rejection. Transplantation (1997) 64(12):1765-1774.
37. Ridge JP, Di Rosa F, Matzinger P: A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature (1998) 393(6684):474-478.
38. Grewal IS, Xu J, Flavell RA: Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand. Nature (1995) 378(6557):617-620.
39. Guo Y, Wu Y, Shinde S, Sy MS, Aruffo A, Liu Y: Identification of a costimulatory molecule rapidly induced by CD40L as CD44H. J Exp Med (1996) 184(3):955-961.
40. Hancock WW, Sayegh MH, Zheng XG, Peach R, Linsley PS, Turka LA: Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection. Proc Natl Acad Sci USA (1996) 93(24):13967-13972.
41. Ranheim EA, Kipps TJ: Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med (1993) 177(4):925-935.
42. Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Buhlman J, Xu J, Flavell RA, Korngold R, Noelle R, Vallera DA: Blockade of CD40 ligand-CD40 interaction impairs CD4+ T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation. J Immunol (1997) 158(1):29-39.
43. Noelle RJ: CD40 and its ligand in host defense. Immunity (1996) 4(5):415-419.
44. Denton MD, Reul RM, Dharnidharka VR, Fang JC, Ganz P, Briscoe DM: Central role for CD40/CD40 ligand (CD154) interactions in transplant rejection. Pediatr Transplant (1998) 2(1):6-15.
45. Kirk AD, Burkly LC, Batty DS, Baumgartner RE, Berning JD, Buchanan K, Fechner JH Jr, Germond RL, Kampen RL, Patterson NB, Swanson SJ et al: Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med (1999) 5(6):686-693.
46. Parker DC, Greiner DL, Phillips TE, Appel MC, Steele SW, Durie FH, Noelle RJ, Mordes JP, Rossini AA: Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc Natl Acad Sci USA (1995) 92(21):9560-9564.
47. Rossini AA, Parker DC, Phillips NE, Durie FH, Noelle RJ, Mordes JP, Greiner DL: Induction of immunological tolerance to islet allografts. Cell Transplant (1996) 5(1):49-52.
48. Rothstein DM, Livak MF, Kishimoto K, Ariyan C, Qian HY, Fecteau S, Sho M, Deng S, Zheng XX, Sayegh MH, Basadonna GP: Targeting signal 1 through CD45RB synergizes with CD40 ligand blockade and promotes long term engraftment and tolerance in stringent transplant models. J Immunol (2001) 166(1):322-329.
49. Markees TG, Serreze DV, Phillips NE, Sorli CH, Gordon EJ, Shultz LD, Noelle RJ, Woda BA, Greiner DL, Mordes JP, Rossini AA: NOD mice have a generalized defect in their response to transplantation tolerance induction. Diabetes (1999) 48(5):967-974.
50. Kenyon NS, Chatzipetrou M, Tzakis A, Miller J, Alejandro R, Ricordi C: Allogeneic hematopoietic stem cell transplantation in recipients of cellular or solid organ allografts. Cancer Treat Res (1999) 101:109-132.
51. Kenyon NS, Chatzipetrou M, Masetti M, Ranuncoli A, Oliveira M, Wagner JL, Kirk AD, Harlan DM, Burkly LC, Ricordi C: Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154. Proc Natl Acad Sci USA (1999) 96(14):8132-8137.
52. Lehnert AM, Yi S, Burgess JS, O'Connell PJ: Pancreatic islet xenograft tolerance after short-term costimulation blockade is associated with increased CD4+ T cell apoptosis but not immune deviation. Transplantation (2000) 69(6):1176-1185.
53. Molano RD, Berney T, Li H, Cattan P, Pileggi A, Vizzardelli C, Kenyon NS, Ricordi C, Burkly LC, Inverardi L: Prolonged islet graft survival in NOD mice by blockade of the CD40-CD154 pathway of T-cell costimulation. Diabetes (2001) 50(2):270-276.
54. Schuler W, Bigaud M, Di Padova F, Geisse S, Gram H, Hungerford V, Kleuser B, Kristofic C, Kunkler A, Menninger K, Riesen S et al: ABI793, a novel, fully human anti-CD154 monoclonal antibody: Efficacy in cynomolgus monkey kidney allotransplantation. Am J Transplant (2003) 3(Suppl 5):Abs 545.
55. Kanmaz T, Fechner JH, Torrealba J, Kim HT, Dong Y, Oberley TD, Schultz JM, Schuler W, Hu H, Hamawy MM, Knechtle SJ: Monotherapy with the human anti-CD154 monoclonal antibody ABI793 prolongs allograft survival in rhesus monkeys. Am J Transplant (2003) 3(Suppl 5):Abs 599.
56. Preston EH, Xu H, Pearl JP, Leopardi FV, Hale DA, Johnson LB, Harlan DM, Kirk AD: Prolonged rejection-free renal allograft survival with the Anti-CD154 antibody IDEC-131 combined with donor-specific transfusion (DST) and sirolimus in non-humans primates (NHPs). Am J Transplant (2003) 3(Suppl 5):Abs 600.
57. Xu H, Montgomery SP, Preston EH, Tadaki DK, Hale DA, Harlan DM, Kirk AD: Studies investigating pretransplant donor-specific blood transfusion, rapamycin, and the CD154-specific antibody IDEC-131 in a nonhuman primate model of skin allotransplantation. J Immunol (2003) 170(5):2776-2782.
58. Adams AB, Shirasugi N, Strobert EA, Cowan SR, Rees PA, Hendrix R, Kenyon NS, Pearson TC, Larsen CP: Combined blockade of the CD40 and CD28 pathways synergizes to promote allograft survival in a non-human primate model. Am J Transplant (2003) 3(Suppl 5):Abs 645.
59. Li Y, Li XC, Zheng XX, Wells AD, Turka LA, Strom TB: Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med (1999) 5(11):1298-1302.
60. Wells AD, Li XC, Walsh MC, Zheng XX, Wu Z, Nunez G, Tang A, Sayegh M, Hancock WW, Strom TB et al: Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med (1999) 5(11):1303-1307. Describes how the preservation of T-cell apoptosis is key to the tolerance via the co-stimulation blockade.
61. Yang Y, Wilson JM: CD40 ligand-dependent T cell activation: Requirement of B7-CD28 signaling through CD40. Science (1996) 273(5283):1862-1864.
62. Larsen CP, Elwood ET, Alexander DZ, Ritchie SC, Hendrix R, Tucker-Burden C, Cho HR, Aruffo A, Hollenbaugh D, Linsley PD, Winn KJ et al: Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature (1996) 381(6581):434-438.
63. Kirk AD, Harlan DM, Armstrong NN, Davis TA, Dong Y, Gray GS, Hong X, Thomas D, Fechner JH Jr, Knechtle SJ: CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA (1997) 94(16):8789-8794.
64. Joosten SA, Van Kooten C, Paul LC: Pathogenesis of chronic allograft rejection. Transplant Int (2003) 16(3):137-145.
65. Russell ME, Hancock WW, Akalin E, Wallace AF, Glysing-Jensen T, Willett TA, Sayegh MH: Chronic cardiac rejection in the LEW to F344 rat model. Blockade of CD28-B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis. J Clin Invest (1996) 97(3):833-838.
66. Azuma H, Chandraker A, Nadeau K, Hancock W, Carpenter CB, Tilney NL, Sayegh MHL: Blockade of T-cell costimulation prevents development of experimental chronic renal allograft rejection. Proc Natl Acad Sci USA (1996) 93(22):12439-12444.
67. Chandraker A, Russell ME, Glysing-Jensen T, Willett TA, Sayegh MH: T-cell costimulatory blockade in experimental chronic cardiac allograft rejection: Effects of cyclosporine and donor antigen. Transplantation (1997) 63(8):1053-1058.
68. Schonbeck U, Mach F, Sukhova GK, Murphy C, Bonnefoy JY, Fabunmi RP, Libby P: Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: A role for CD40 signaling in plaque rupture? Circ Res (1997) 81(3):448-454.
69. Hancock WW, Buelow R, Sayegh MH, Turka LA: Antibody-induced transplant arteriosclerosis is prevented by graft expression of antioxidant and anti-apoptotic genes. Nat Med (1998) 4(12):1392-1396.
70. Takada M, Chandraker A, Nadeau KC, Sayegh MH, Tilney NL. The role of the B7 costimulatory pathway in experimental cold ischemia/reperfusion injury. J Clin Invest (1997) 100(5):1199-1203.
71. Shen XD, Ke B, Zhai Y, Amersi F, Gao F, Anselmo DM, Busuttil RW, Kupiec-Weglinski JW: CD154-CD40 T-cell costimulation pathway is required in the mechanism of hepatic ischemia/reperfusion injury, and its blockade facilitates and depends on heme oxygenase-1 mediated cytoprotection. Transplantation (2002) 74(3):315-319.
72. Abdi R, Means TK, Luster AD: Chemokines in islet allograft rejection. Diabetes Metab Res Rev (2003) 19(3):186-190.
73. Ozkaynak E, Gao W, Shemmeri N, Wang C, Gutierrez-Ramos JC, Amaral J, Qin S, Rottman JB, Coyle AJ, Hancock WW: Importance of ICOS-B7RP-1 costimulation in acute and chronic allograft rejection. Nat Immunol (2001) 2(7):591-596.
74. Nanji A, Hancock WW, Anderson CC, Adams AB, Luo B, Wong L, Coyle AJ, Larsen CP, Shapiro AMJ: Targeting the ICOS-B7H costimulatory pathway synergizes with rapamycin to regulate alloresponses in islet transplantation. Am J Transplant (2003) 3(Suppl 5):Abs 547.
75. Kosuge H, Suzuki J, Gotoh R, Koga N, Ito H, Isobe M, Inobe M, Uede T: Induction of immunologic tolerance to cardiac allograft by simultaneous blockade of inducible co-stimulator and cytotoxic T-lymphocyte antigen 4 pathway. Transplantation (2003) 75(8):1374-1379.
76. Yuan X, Salama A, Schmitt I, Dong VM, Chandraker A, Yagita H, Sayegh MH: The role of CD134-CD134L and CD28-B7 pathways in pre-sensitized alloimmune responses. J Transplant (2003) 3(S5):Abs 479.
77. Demirci G, Amanullah F, Salama A, Strom TB, Sayegh MH, Li XC: OX40 costimulates CD28 and CD154 independent rejection. Am J Transplant (2003) 3(Suppl 5):Abs 524.
78. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF et al.: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med (2000) 192(7):1027-1034.
79. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, Greenfield EA et al: PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol (2001) 2(3):261-268.
80. Eppihimer MJ, Gunn J, Freeman GJ, Greenfield EA, Chernova T, Erickson J, Leonard JP: Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells. Microcirculation (2002) 9(2):133-145.
81. Ansari MJ, Salama AD, Chitnis T, Smith RN, Yagita H, Akiba H, Yamazaki T, Azuma M, Iwai H, Khoury SJ, Auchincloss H Jr et al: The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med (2003) 198(1):63-69.
82. Salama AD, Chitnis T, Imitola J, Ansari M, Akiba H, Tushima F, Azuma M, Yagita H, Sayegh MH, Khoury SJ: Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J Exp Med (2003) 198(1):71-78.
83. Hancock WW, Wang L, Ozkaynak E, Wells AD, Han R, Chen L, Coyle AJ: The PD-1/PD-L1 pathway regulates T cell all-activation and organ injury. Am J Transplant (2003) 3(Suppl 5):Abs 72.
84. Gao W, Demirci G, Strom TB, Li XC: Blocking CD154 co-stimulation concurrent with stimulating PD-1 negative signals induces long-term islet allograft survival. Am J Transplant (2003) 3(Suppl 5):Abs 1108.